Sample dispatch and sample delivery

A Swiss company with a wholesale license was looking for new solutions for shipping drug samples and drafting internal guidelines for sample distribution to pharmacies and drugstores.

We supported the company in selecting a transport service provider and drafted contracts to ensure that the transport complies with Good Distribution Practice (GDP) and that the medicines are not damaged.

Together, we drafted internal guidelines (Standard Operating Procedure, SOP) that clearly and simply specify the quantities in which samples for professionals and the general public can be distributed to professionals in drugstores and pharmacies in accordance with the provisions of the Ordinance on the Advertising of Medicinal Products (AWV). This enabled the company to simplify its processes and ensure that samples were distributed in accordance with Swiss law.

Grüezi Schwiiz / Hello Switzerland

Gaining a foothold in the Swiss pharmaceutical market with customised solutions

An EU marketing authorisation holder for various medicinal products has decided to establish itself in Switzerland. Until now, third-party providers had been responsible for supplying the medicinal products to the Swiss market on its behalf. We provided legal support for the transfer of Swiss marketing authorisations and the granting of all operating licences, and in particular also structured the orderly termination and replacement of the existing contractual arrangements. Together, we planned and successfully implemented solutions tailored to the group’s specific structure, thereby laying the foundation for the company’s independent business operations in Switzerland.

From A to B via CH

International distribution of medicinal products

An internationally active pharmaceutical company based in Switzerland manages the Europe‑wide distribution of its medicinal products from Switzerland. The key questions were under which conditions direct deliveries between EU countries with administrative processing via Switzerland are possible and which authorisations are required for this purpose.
All players in the pharmaceutical supply chain must comply with the principles of good manufacturing practice (GMP) and good distribution practice (GDP) in order to protect patients from falsified medicinal products entering the legal supply chain. Drawing on our experience in Swiss and European pharmaceutical law as well as in matters relating to the bilateral agreements (Mutual Recognition Agreement, MRA), we were able to contribute to the design of the distribution structure.